A novel prognostic risk model for patients with refractory/relapsed acute myeloid leukemia receiving venetoclax plus hypomethylating agents. - Shahswar R; Gabdoulline R; Krueger K; Wichmann M; Götze KS; Braitsch K; Meggendorfer M; Schmalbrock L; Bullinger L; Modemann F; Fiedler W; Krauter J; et al. (Leukemia, 2025)